Stocklytics Platform
Asset logo for symbol VRDN
Viridian Therapeutics
VRDN58
$13.89arrow_drop_up7.25%$0.94
Asset logo for symbol VRDN
VRDN58

$13.89

arrow_drop_up7.25%

Income Statement (VRDN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$56.04M-$65.94M-$51.35M-$54.89M-$72.47M
EBITDA-$55.89M-$65.79M-$51.22M-$54.76M-$67.98M
gross Profit-$273.00K-$278.00K-$263.00K-$360.00K-$107.00K
NET Income-$48.54M-$66.86M-$47.66M-$55.06M-$68.04M
total Revenue$72.00K$72.00K$72.00K$72.00K$98.00K

Balance Sheet (VRDN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$71.31M-$81.77M-$90.77M-$81.57M-$83.20M
stockholders Equity$582.53M$442.02M$283.57M$315.85M$350.54M
total Assets$630.38M$490.42M$328.75M$351.46M$386.64M
total Debt$20.32M$21.04M$20.82M$5.51M$5.31M
total Liabilities$47.85M$48.40M$45.18M$35.61M$36.09M

Cash Flow (VRDN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$177.08M$198.94M$15.45M$3.06M$8.20M
free Cash Flow-$45.22M-$38.04M-$39.38M-$45.54M-$62.08M
investing Cash Flow---$40.71M-$13.29M
operating Cash Flow-$45.22M-$38.00M-$38.98M-$45.21M-$61.97M

Viridian Therapeutics (VRDN) Financials

Viridian Therapeutics, Inc. (VRDN) is a biotechnology company that focuses on developing innovative therapies for the treatment of serious diseases. The company's financials reflect its commitment to driving growth and delivering value to its stockholders. When analyzing Viridian's income statement, it is evident that the company has generated impressive revenues. Additionally, the gross profit indicates the profitability of its operations.

One key metric to evaluate the company's financial performance is EBIT (Earnings Before Interest and Taxes). Viridian's EBIT demonstrates its ability to generate profits from its core business activities. Moreover, EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) provides further insights into the company's operational efficiency.

Viridian's net income from stockholders reflects the company's profitability after deducting all expenses and taxes. This metric showcases the financial benefit received by stockholders. Furthermore, the company's total revenue encompasses all the income generated from its various sources.

Analyzing Viridian's balance sheet, it is clear that the company has strong financial standing. The company's cash equivalents represent its readily available cash and short-term investments. Additionally, net debt indicates the amount of debt Viridian has after subtracting its cash and cash equivalents.

Stockholders' equity demonstrates the residual value of the assets after deducting liabilities. Viridian's stockholders' equity reflects the financial health and value of the company. Total assets encompass all the resources owned by the company, while total debt represents its overall liabilities.

When examining Viridian's cash flow, it is essential to assess its financing, investing, and operating activities. The financing cash flow reflects the funds received or paid out to finance the company's operations or expansion. In contrast, the investing cash flow indicates the capital invested in assets or divested from them.

Operating cash flow reflects the cash generated from the company's core operations. This metric provides insights into the company's ability to generate cash from its day-to-day business activities. Lastly, free cash flow represents the cash remaining after deducting capital expenditures from operating cash flow. It reflects the company's financial flexibility and potential for growth.

add Viridian Therapeutics to watchlist

Keep an eye on Viridian Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level